Third Quarter 2026
Filed Oct 29, 2026Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
EMPEROR enrollment is complete and the Company reported continued patient progression with no treatment discontinuations, while quarterly revenue increased modestly. However, the Company reported a wider net loss and higher research and development and sales, general and administrative expenses as it advances zorevunersen and launch readiness.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $11.26M | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $59.83M | – | – |
| Sales, general and administrative expenses, three months ended September 30, 2026GAAP | $28.74M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $88.57M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$77.31M | – | – |
| Interest income (expense), net, three months ended September 30, 2026GAAP | $3.67M | – | – |
| Other income, three months ended September 30, 2026GAAP | $6K | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | −$73.64M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$73.64M | – | – |
| Net loss per share, basic, three months ended September 30, 2026GAAP | $(1.08) | – | – |
| Net loss per share, diluted, three months ended September 30, 2026GAAP | $(1.08) | – | – |
| Weighted-average common shares outstanding, basic, three months ended September 30, 2026GAAP | 68,362,880 | – | – |
| Weighted-average common shares outstanding, diluted, three months ended September 30, 2026GAAP | 68,362,880 | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$74.15M | – | – |
| Revenue, nine months ended September 30, 2026GAAP | $26.81M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $149.0M | – | – |
| Sales, general and administrative expenses, nine months ended September 30, 2026GAAP | $73.97M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $223.0M | – | – |
| Loss income from operations, nine months ended September 30, 2026GAAP | −$196.2M | – | – |
| Net loss income, nine months ended September 30, 2026GAAP | −$185.3M | – | – |
| Net loss income per share, basic, nine months ended September 30, 2026GAAP | $(2.81) | – | – |
| Net loss income per share, diluted, nine months ended September 30, 2026GAAP | $(2.81) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $107.3M | – | – |
| Marketable securities - current, September 30, 2026GAAP | $211.9M | – | – |
| Marketable securities - long-term, September 30, 2026GAAP | $39.60M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Into early 2028 outlook
- Note$358.8 million in cash, cash equivalents and marketable securities as of September 30, 2026 expected to fund operations into early 2028
- NoteData readout from the 162-patient primary analysis population in the Phase 3 EMPEROR study anticipated in the third quarter of 2027
- NotePlanned U.S. NDA submission for zorevunersen in the second half of 2027
- NoteDosing of the third STK-002 cohort expected to complete by the end of 2026
- NoteDosing of the fourth STK-002 cohort expected to follow in early 2027
- NoteInitial safety and efficacy results from the latter STK-002 cohorts anticipated in the first half of 2027
- NotePotential U.S. approval and launch in early 2028
What drove it
- Quarterly revenue was generated from satisfying contractual obligations of the collaboration and licensing agreements with Acadia and Biogen.
- The increase in research and development expenses was driven by increased activities and personnel expenses to support the advancement of zorevunersen.
- The increase in sales, general and administrative expenses was driven by growth in personnel and launch readiness expenses.
- Global enrollment of 162 patients in the EMPEROR primary analysis population was completed in June 2026.
- Enrollment of 34 patients in Europe was completed in August 2026, and enrollment of 5 patients in China was completed in October 2026.
- Dosing is complete in the first two STK-002 cohorts, and dosing of the third cohort is underway.
Concerns
- Net loss for the three months ended September 30, 2026 was $73.6 million, compared to a net loss of $38.3 million for the same period in 2025.
- Revenue for the nine months ended September 30, 2026 was $26.8 million, compared to $183.0 million for the same period in 2025, primarily due to recognition of $150.8 million related to the Biogen IP license performance obligation during the nine months ended September 30, 2025.
- Zorevunersen is currently in clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.
- The EMPEROR Phase 3 data readout is anticipated in the third quarter of 2027.
What to watch
- Phase 3 EMPEROR data readout anticipated in the third quarter of 2027.
- Submission of data throughout the first half of 2027 to support rapid completion of the planned U.S. NDA submission in the second half of 2027.
- Progression of EMPEROR patients through Week 52 and the open-label treatment period.
- Completion of third-cohort STK-002 dosing by the end of 2026 and expected fourth-cohort dosing in early 2027.
- Initial STK-002 safety and efficacy data anticipated in the first half of 2027.
- Cash runway expected to fund operations into early 2028.
Balance sheet and cash flow
- $358.8 million in cash, cash equivalents and marketable securities as of September 30, 2026
- Cash and cash equivalents were $107,271 (in thousands) as of September 30, 2026, compared to $84,220 (in thousands) as of December 31, 2025.
- Marketable securities - current were $211,916 (in thousands) as of September 30, 2026, compared to $200,450 (in thousands) as of December 31, 2025.
- Marketable securities - long-term were $39,602 (in thousands) as of September 30, 2026, compared to $106,260 (in thousands) as of December 31, 2025.
- Total assets were $406,692 (in thousands) as of September 30, 2026, compared to $418,434 (in thousands) as of December 31, 2025.
- Total liabilities were $54,104 (in thousands) as of September 30, 2026, compared to $65,977 (in thousands) as of December 31, 2025.
- Total stockholders’ equity was $352,588 (in thousands) as of September 30, 2026, compared to $352,457 (in thousands) as of December 31, 2025.
- No operating cash flow, free cash flow, debt, repurchases, or dividends were reported.
Analysis
Stoke reported third-quarter revenue of $11.3 million, compared with $10.6 million for the same period in 2025. Revenue is generated from contractual obligations under collaboration and licensing agreements with Acadia and Biogen. The quarterly operating loss was $77.3 million and net loss was $73.6 million, or $1.08 per share, compared with a $38.3 million net loss, or $0.65 per share, in the prior-year quarter.
Spending increased as the Company advanced zorevunersen and prepared for a potential launch. Research and development expense was $59.8 million versus $37.7 million in the prior-year quarter, driven by increased activities and personnel expenses supporting zorevunersen. Sales, general and administrative expense increased to $28.7 million from $16.0 million, driven by personnel growth and launch readiness expenses. For the nine months, revenue fell to $26.8 million from $183.0 million, primarily because the prior-year period included $150.8 million related to the Biogen IP license performance obligation.
The central operating update was continued execution of the Phase 3 EMPEROR study. Enrollment of 162 patients in the United States, United Kingdom and Japan primary analysis population was completed in June 2026. As of October 29, 2026, approximately 110 patients were through Week 28, approximately 20 were through Week 52, and all of those patients were continuing into the open-label treatment period. The Company stated that no patients had discontinued treatment. Stoke expects a data readout in the third quarter of 2027 and plans to submit its U.S. NDA in the second half of 2027.
Stoke also reported progress in its earlier-stage ADOA program. The first two STK-002 cohorts have completed dosing, the third cohort is underway, and the Company expects third-cohort dosing to complete by the end of 2026. The fourth cohort is expected in early 2027, with initial safety and efficacy results from the latter cohorts anticipated in the first half of 2027. The Company reported $358.8 million in cash, cash equivalents and marketable securities as of September 30, 2026 and expects this position to fund operations into early 2028.
Management, verbatim
The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when the primary endpoint of change in major motor seizure frequency is measured and approximately 20 are through Week 52, the end of the treatment period. All 20 of these patients are continuing into the open-label extension period of the study and to date, no patients have discontinued treatment.
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
Our NDA planning is on track following our recent discussion with the FDA. Importantly, the key secondary endpoint of changes in patients' cognition and behavior will be measured using a multicomponent assessment of four Vineland-3 subdomains. This multicomponent measure reflects the diversity of effects that people with Dravet syndrome experience and how to best evaluate them in a clinical trial. We look forward to the Phase 3 data readout in the third quarter of 2027 and completing our NDA submission in the second half of 2027.
Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
Not in the filing
stated, not guessed- Gross profit and gross margin
- Segment revenue
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Prior-quarter financial comparisons
- Numeric year-over-year percentage changes for reported financial metrics
- Financial revenue, operating expense, gross margin, or tax-rate guidance
- Previous-release outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.